Sermorelin vs CJC-1295
Two GHRH analogues with fundamentally different pharmacokinetics—Sermorelin offers short-acting physiological pulses with clinical approval history, while CJC-1295 provides extended GH elevation for research convenience.
Last updated: 2026-02-02
Sermorelin and CJC-1295 represent two generations of Growth Hormone Releasing Hormone (GHRH) analogues, both designed to stimulate the pituitary gland's natural production of growth hormone. While they share a common mechanism—activating the GHRH receptor—their pharmacokinetic profiles differ dramatically.
Sermorelin, the first synthetic GHRH analogue, closely mimics natural GHRH with a short half-life and pulsatile action. It achieved FDA approval for paediatric GH deficiency before being discontinued for commercial reasons. CJC-1295, developed later, incorporates modifications that extend its half-life from minutes to days, providing sustained GH elevation.
This comparison examines the molecular differences, research findings, theoretical protocols, and practical considerations for each GHRH analogue, including the distinction between CJC-1295 with and without DAC (Drug Affinity Complex).
**Important Disclaimer:** This content is for educational and research purposes only. Sermorelin's approval was withdrawn and CJC-1295 has never been approved for human use. Both are prohibited in competitive sports by WADA.
Quick Comparison Table
| Category | Sermorelin | CJC-1295 |
|---|---|---|
| Peptide Class | GHRH analogue (first generation) | GHRH analogue (modified/extended) |
| Structure | 29 amino acids (GHRH 1-29) | 30 amino acids with modifications (or Mod GRF 1-29) |
| Half-Life | 10-20 minutes | ~30 min (no DAC) or 6-8 days (with DAC) |
| GH Release Pattern | Pulsatile (mimics natural physiology) | Sustained elevation (with DAC) or pulsatile (Mod GRF) |
| Regulatory History | Was FDA-approved (Geref®), now discontinued | Never approved for human use |
| Administration Frequency | 1-3 times daily (subcutaneous) | Once weekly (DAC) or 1-3x daily (Mod GRF) |
| GHRP Synergy | Yes—enhances GH pulse when combined | Yes—synergistic with all GHRPs |
| IGF-1 Elevation | Moderate, physiological pattern | Sustained elevation (DAC) or moderate (Mod GRF) |
| Somatostatin Sensitivity | Full sensitivity (natural regulation) | Full sensitivity (natural regulation maintained) |
| Clinical Data | Extensive (was approved medication) | Limited human trials (research compound) |
| Typical Research Use | Anti-ageing, GH optimisation, paediatric research | Body composition, recovery, convenience protocols |
| Cost Consideration | Moderate (requires frequent dosing) | Higher per dose, but less frequent (DAC) |
GHRH Receptor Activation: Same Target, Different Kinetics
Sermorelin
Sermorelin Mechanism of Action
Sermorelin (GHRH 1-29) is a truncated analogue of endogenous GHRH, containing the first 29 amino acids of the 44-amino acid native hormone. This N-terminal fragment retains full biological activity, as the receptor-binding and activation regions are contained within these 29 residues.
Key Mechanistic Features:
• **GHRH Receptor Binding:** Sermorelin binds to GHRH receptors (GHRH-R) on pituitary somatotrophs, triggering cyclic AMP (cAMP) production and subsequent GH release from secretory vesicles.
• **Pulsatile Release Pattern:** Due to its short half-life (~10-20 minutes), sermorelin produces discrete GH pulses that closely mimic natural GHRH secretion. This pulsatile pattern is considered more physiological than sustained GH elevation.
• **Somatostatin Regulation:** Sermorelin's effects are subject to normal somatostatin inhibition, maintaining the body's natural GH feedback mechanisms. GH release is enhanced during natural secretory windows and suppressed during somatostatin-dominant periods.
• **IGF-1 Pathway:** GH released in response to sermorelin stimulates hepatic IGF-1 production, maintaining normal GH/IGF-1 axis dynamics.
• **Synergy with GHRPs:** When combined with growth hormone releasing peptides (which work via the ghrelin receptor), sermorelin shows synergistic effects, producing GH pulses 5-10x greater than either agent alone.
Clinical Significance: Sermorelin's physiological action pattern made it attractive for conditions where maintaining normal GH rhythms was desirable. Its approval for paediatric GH deficiency demonstrated clinical viability before commercial discontinuation.
CJC-1295
CJC-1295 Mechanism of Action
CJC-1295 exists in two primary forms: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC (also known as Mod GRF 1-29 or Modified GRF). Understanding both is essential for research applications.
CJC-1295 with DAC:
• **DAC Technology:** The Drug Affinity Complex is a chemical modification that allows CJC-1295 to bind to serum albumin after injection. This dramatically extends half-life from minutes to 6-8 days.
• **Sustained GH Elevation:** Rather than producing discrete pulses, CJC-1295 with DAC maintains elevated GH levels over days. This is pharmacologically convenient but less physiological than natural pulsatile release.
• **Blunted Amplitude:** While providing sustained elevation, the pulse amplitude may be blunted compared to short-acting analogues. Some researchers theorise this could affect downstream IGF-1 dynamics.
CJC-1295 without DAC (Mod GRF 1-29):
• **Modified Sequence:** Four amino acid substitutions (positions 2, 8, 15, and 27) protect against enzymatic degradation, extending half-life to ~30 minutes vs sermorelin's ~10-20 minutes.
• **Pulsatile Pattern Preserved:** Without DAC, Mod GRF 1-29 produces pulsatile GH release similar to sermorelin but with improved stability and potentially more consistent dosing.
• **Preferred for GHRP Combinations:** Mod GRF 1-29 is often preferred over DAC versions when combining with GHRPs, as the pulsatile pattern maximises synergistic effects.
Both Forms: • Activate GHRH receptors on pituitary somatotrophs • Subject to somatostatin regulation • Synergistic with GHRPs through complementary receptor pathways
Clinical Trial Evidence
Sermorelin Clinical Studies
Design: Review
In conclusion, peptides represent a new phase in performance enhancement but remain experimental substances with poorly defined long-term risks. Until longitudinal data clarify their safety and prevalence, peptide use in both competitive and recreational settings should be considered high-risk and ethically problematic.
View study — PubMed 41880199Design: Review
We summarise structural characteristics, pharmacologic effects, and commonly reported dosing patterns, and we synthesise clinically relevant adverse effects with particular attention to hormonal imbalance, endocrine-metabolic risk, and biologically plausible but unproven mitogenic concerns.
View study — PubMed 42395176Design: Review
The effect of PEG molecular weight, number of PEG chains bound and position of PEGylation site on GRF activity were investigated. Mono-PEGylated isomers with a PEG5000 polymer chain linked to Lys 12 or Lys 21 residues, showed high biological activity in vitro, which is similar to that of hGRF1-29, and a higher pharmacodynamic response as compared to unmodified GRF molecule.
View study — PubMed 14499707Design: Study
5-0. 75 ng/mL) demonstrated sufficient sensitivity for effective detection and confirmation analysis of the target peptides in urine.
View study — PubMed 41138283CJC-1295 Clinical Studies
Design: Randomised controlled trial
Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC-1295 as a therapeutic agent.
View study — PubMed 16352683Design: Clinical trial
CJC-1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility. The marked enhancement of trough GH levels by continuous GHRH stimulation implicates the importance of this effect on increasing IGF-I. Long-acting GHRH preparations may have clinical utility in patients with intact pituitary GH secretory capability.
View study — PubMed 17018654Design: Review
While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown.
View study — PubMed 41476424Design: Review
In conclusion, peptides represent a new phase in performance enhancement but remain experimental substances with poorly defined long-term risks. Until longitudinal data clarify their safety and prevalence, peptide use in both competitive and recreational settings should be considered high-risk and ethically problematic.
View study — PubMed 41880199Benefits Comparison
Sermorelin Unique Benefits
- Most physiological GH release pattern among GHRH analogues
- Extensive clinical history with established safety data from FDA approval
- Maintains natural somatostatin regulation and GH feedback
- Well-suited for anti-ageing and GH optimisation research
- Lower risk of sustained IGF-1 elevation concerns
- Documented efficacy in paediatric GH deficiency (historical approval)
- Better characterised pharmacokinetics from clinical development
- May be preferred for subjects with insulin sensitivity concerns
Shared Benefits
- Both stimulate endogenous GH production (not exogenous replacement)
- Maintain natural GH feedback mechanisms
- Synergistic with growth hormone releasing peptides
- Support IGF-1 elevation through physiological pathways
- Do not cause pituitary desensitisation at appropriate doses
- Both may support body composition, recovery, and anti-ageing research
- Subject to somatostatin regulation (natural braking mechanism)
- Generally considered lower risk than exogenous HGH administration
CJC-1295 Unique Benefits
- Extended half-life reduces injection frequency (DAC: weekly dosing)
- Mod GRF 1-29 offers improved stability over sermorelin
- More convenient protocols for compliance-challenged research
- Sustained GH elevation may benefit certain research applications
- Mod GRF 1-29 produces robust synergy with GHRPs
- Greater flexibility in protocol design (DAC vs no-DAC options)
- Potentially more consistent blood levels with DAC version
- Well-established in research community with substantial anecdotal data
Research & Evidence
Sermorelin Research
Sermorelin Research Summary
Sermorelin has the most extensive clinical documentation among GHRH analogues, having completed full FDA approval and post-marketing experience.
Clinical Trial History:
• Paediatric GH Deficiency: Sermorelin (as Geref®) was FDA-approved in 1997 for diagnosis and treatment of paediatric GH deficiency. Clinical trials demonstrated effective GH stimulation and growth velocity improvements in deficient children.
• Adult GH Deficiency: Studies in adults showed sermorelin could increase GH secretion and IGF-1 levels, though with variable response rates. Some subjects showed robust responses while others had limited benefit.
• Anti-Ageing Research: Multiple studies examined sermorelin in elderly subjects with age-related GH decline. Results showed improved GH secretion, though the degree of clinical benefit (body composition, energy, etc.) varied across studies.
• Safety Profile: Clinical development and post-marketing surveillance established a favourable safety profile with primarily injection-site reactions and transient flushing as common effects.
Key Publications: - Vittone J et al. "Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men" (Metabolism, 1997) - Walker RF. "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" (Clin Interv Aging, 2006)
Discontinuation Note: Sermorelin was voluntarily discontinued in 2008 for commercial/manufacturing reasons, not safety concerns. Its clinical data remains valuable for understanding GHRH analogue pharmacology.
CJC-1295 Research
CJC-1295 Research Summary
CJC-1295 development focused on creating a longer-acting GHRH analogue, with research primarily conducted by ConjuChem Biotechnologies.
Clinical Development:
• Phase I/II Trials: CJC-1295 with DAC underwent early clinical trials showing dose-dependent GH and IGF-1 elevation sustained over days following single injections. Subjects showed 2-10 fold increases in GH levels.
• Pharmacokinetic Studies: Research confirmed the extended half-life (6-8 days) with DAC and demonstrated sustained IGF-1 elevation for up to 2 weeks following administration.
• Development Termination: Clinical development was halted following adverse events in trials (one death, though causality debated). The peptide never achieved regulatory approval.
Mod GRF 1-29 Research:
• Stability Studies: Research demonstrated improved enzymatic stability compared to native GHRH and sermorelin, with preserved biological activity.
• Synergy Documentation: Studies with GHRP combinations showed synergistic GH release, supporting the dual-receptor approach used in many research protocols.
Key Considerations: - Less clinical data than sermorelin (no approval achieved) - Pharmacokinetic advantages vs safety/approval questions - Research community has accumulated substantial experience despite limited formal trials
Publications: - Teichman SL et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295" (J Clin Endocrinol Metab, 2006) - Ionescu M, Bhador LP. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295" (Growth Horm IGF Res, 2006)
Head-to-Head Analysis
Sermorelin vs CJC-1295: Direct Comparison
No formal head-to-head clinical trials directly compare sermorelin and CJC-1295. However, comparative analysis of available data reveals key differences:
GH Release Characteristics: - Sermorelin: Peak GH at 30-60 minutes, returning to baseline within 2-3 hours - Mod GRF 1-29: Similar pattern with slightly extended duration - CJC-1295 with DAC: Sustained elevation over days, blunted peak amplitude
IGF-1 Response: - Sermorelin: Moderate IGF-1 elevation with physiological oscillation - CJC-1295 with DAC: Sustained IGF-1 elevation, potentially more consistent but less physiological
Clinical Validation: - Sermorelin: FDA-approved, extensive safety database, known efficacy parameters - CJC-1295: Phase I/II only, limited safety data, development discontinued
Practical Research Considerations: - Sermorelin requires 1-3x daily administration - Mod GRF 1-29 requires similar frequency - CJC-1295 with DAC allows weekly or twice-weekly dosing
Synergy with GHRPs: Both show synergistic effects with GHRPs. Mod GRF 1-29 is generally preferred over CJC-1295 with DAC for combination protocols, as the pulsatile release pattern maximises the synergistic GH pulse amplitude.
Expert Opinion (Research Community): Many researchers favour Mod GRF 1-29 + GHRP combinations for optimised pulsatile GH release, reserving DAC versions for convenience-prioritised protocols. Sermorelin remains respected for its clinical history but may be considered slightly less stable than Mod GRF 1-29.
Protocol Comparison
Sermorelin Protocol
Sermorelin Theoretical Research Protocols
Educational purposes only—not medical advice. Consult a qualified healthcare professional.
Standard Research Protocol: • Dosage: 100-300 mcg per administration • Frequency: Once daily (before bed) or 2-3 times daily • Timing: On empty stomach; pre-bed dosing capitalises on natural nocturnal GH secretion • Duration: 3-6 month cycles typical in research settings
Anti-Ageing / GH Optimisation Protocol: • Sermorelin: 200-300 mcg • Timing: 30-60 minutes before bed (empty stomach) • Frequency: Daily or 5 days on/2 days off • Rationale: Enhance natural sleep-associated GH pulse
Combination Protocol (with GHRP): • Sermorelin: 100-200 mcg • GHRP-2 or Ipamorelin: 100 mcg • Timing: Administered together, 2-3 times daily • Expected: Synergistic GH pulse 5-10x baseline
Reconstitution and Storage: • Reconstitute with bacteriostatic water • Store reconstituted peptide at 2-8°C • Use within 3-4 weeks of reconstitution • Protect from light
Administration Notes: • Subcutaneous injection (abdomen, thigh) • Avoid eating for 2 hours before and 30 minutes after • Fat and carbohydrates blunt GH response
CJC-1295 Protocol
CJC-1295 Theoretical Research Protocols
Educational purposes only—not medical advice. Consult a qualified healthcare professional.
Mod GRF 1-29 (CJC-1295 without DAC):
• Dosage: 100-200 mcg per administration (saturation dose principle) • Frequency: 2-3 times daily • Timing: Upon waking, post-workout, before bed (all on empty stomach) • Duration: 8-16 week research cycles
CJC-1295 with DAC:
• Dosage: 1-2 mg per administration • Frequency: Once or twice weekly • Timing: Any time (long half-life makes timing less critical) • Duration: 8-12 week cycles with breaks
Optimal Combination Protocol (Mod GRF 1-29 + GHRP): • Mod GRF 1-29: 100 mcg • Ipamorelin: 100 mcg (or GHRP-2: 100 mcg) • Frequency: 2-3 times daily (pre-bed dose prioritised) • Timing: Empty stomach, administered together • Expected: Synergistic GH pulse, 5-10x baseline
DAC vs No-DAC Decision: • Choose Mod GRF 1-29 for: Physiological pulsatile release, GHRP combinations, maximum pulse amplitude • Choose CJC-1295 with DAC for: Convenience, reduced injection frequency, sustained IGF-1 elevation
Storage and Handling: • Lyophilised powder stable at -20°C long-term • Reconstitute with bacteriostatic water • Refrigerate at 2-8°C after reconstitution • CJC-1295 with DAC more stable than Mod GRF 1-29 in solution
Combined Use
Using Sermorelin and CJC-1295 Together
Combining sermorelin and CJC-1295 (either form) is generally not practiced, as they activate the same receptor. However, understanding comparative use and transitioning between them is relevant:
Why Not Combine: Both peptides bind GHRH receptors on pituitary somatotrophs. Co-administration provides no synergistic benefit—they compete for the same binding sites. Resources are better allocated to combining GHRH analogue + GHRP for true synergy.
Transitioning Between Them: Some protocols transition from CJC-1295 with DAC to Mod GRF 1-29 or sermorelin: • DAC provides baseline, then add short-acting for enhanced pulses • Not well-validated; primarily anecdotal approaches
The Optimal "Stack": Rather than combining GHRH analogues, the established synergy is: • GHRH analogue (Sermorelin, Mod GRF 1-29, or CJC-1295) • Plus GHRP (Ipamorelin, GHRP-2, or GHRP-6)
This combination activates two distinct receptor systems (GHRH-R and GHS-R1a) for truly synergistic GH release.
Choosing Your GHRH Component: • Sermorelin: For maximum clinical validation and physiological pattern • Mod GRF 1-29: For improved stability over sermorelin with preserved pulsatile action • CJC-1295 with DAC: For convenience when less frequent dosing is prioritised
Example Optimal Protocol: • Mod GRF 1-29: 100 mcg + Ipamorelin: 100 mcg • Administered 2-3 times daily (upon waking, post-workout, pre-bed) • All doses on empty stomach
Safety Profiles
Sermorelin Safety
Sermorelin Safety Profile
Sermorelin has the most established safety profile among GHRH analogues due to its FDA approval history and post-marketing surveillance.
From Clinical Trials and Post-Marketing:
Common Side Effects (>1%): • Injection site reactions (pain, redness, swelling) • Facial flushing (due to vasodilation) • Headache (transient) • Dizziness or lightheadedness • Hyperactivity in paediatric patients
Uncommon Effects: • Nausea • Urticaria (hives) • Taste changes • Chest tightness (rare)
Laboratory Findings: • Transient elevation of GH and IGF-1 (expected pharmacological effect) • No significant effects on glucose, lipids, or other metabolic markers at therapeutic doses
Long-Term Considerations: • Clinical use did not reveal serious long-term adverse effects • Theoretical concerns about sustained IGF-1 elevation apply to all GH-stimulating therapies • No evidence of pituitary desensitisation with appropriate dosing
Contraindications (From Prescribing Information): • Known hypersensitivity to sermorelin or components • Active malignancy • Pregnancy and breastfeeding • Conditions where GH elevation would be dangerous
Advantages: The FDA approval process means sermorelin's safety profile is better characterised than any other GHRH analogue. This provides greater confidence in expected effects and risks.
CJC-1295 Safety
CJC-1295 Safety Profile
CJC-1295's safety profile is less well-characterised due to limited clinical development and lack of regulatory approval.
From Clinical Trials (Limited Data):
Reported Side Effects: • Injection site reactions • Flushing • Headache • Diarrhoea • Nausea • Transient hypotension
Serious Concerns: • Clinical development was halted following adverse events including one death, though direct causation was debated • Long-term safety data does not exist • No post-marketing surveillance (never approved)
CJC-1295 with DAC Specific Concerns:
• Sustained IGF-1 Elevation: The long half-life means IGF-1 remains elevated for extended periods. Chronic elevated IGF-1 has theoretical associations with increased cancer risk in epidemiological studies.
• Loss of Pulsatility: Natural GH secretion is pulsatile. The physiological importance of this pattern vs sustained elevation is debated but potentially significant.
• Difficult to Discontinue Rapidly: If adverse effects occur, the 6-8 day half-life means effects persist long after stopping.
Mod GRF 1-29 Considerations: • Shorter half-life allows better control • Pulsatile pattern may be more physiological • Less long-term safety concern than DAC version • Still lacks formal clinical safety data
General GHRH Analogue Risks: • Effects on glucose metabolism (GH is counter-regulatory to insulin) • Theoretical concerns about tumour growth promotion • Water retention and joint discomfort • Carpal tunnel-like symptoms at high doses
Contraindications (Theoretical): • Active malignancy • Diabetic retinopathy • Pregnancy and breastfeeding • Conditions exacerbated by GH elevation
The Verdict: When to Choose Which?
Choose Sermorelin When:
- Maximum clinical validation and established safety profile are priorities
- Research requires documented regulatory history for institutional approval
- Anti-ageing research where physiological GH patterns are preferred
- Subjects with concerns about sustained IGF-1 elevation
- Protocols requiring confident safety monitoring parameters
- When transitioning from or comparing to historical clinical data
- Conservative approach prioritising known over theoretical benefits
Choose CJC-1295 When:
- Convenience of less frequent dosing is important (DAC version)
- Improved peptide stability is desired (Mod GRF 1-29)
- Research requires sustained GH/IGF-1 elevation (DAC version)
- Combining with GHRPs for maximum synergistic effect (Mod GRF 1-29)
- Body composition or recovery research where convenience aids compliance
- Cost-per-dose considerations favour less frequent administration
- When established research community protocols provide guidance
Consider Combining When:
- Not recommended: Both activate the same GHRH receptor
- Instead, combine chosen GHRH analogue with a GHRP for true synergy
- Example: Mod GRF 1-29 + Ipamorelin for pulsatile optimised GH release
- Example: CJC-1295 with DAC + Ipamorelin for sustained + pulsed approach
Frequently Asked Questions
Conclusion
## Sermorelin vs CJC-1295: Summary
Sermorelin and CJC-1295 represent different approaches to GHRH-based GH stimulation, each with distinct advantages for research applications.
Sermorelin offers the strongest clinical validation, having achieved FDA approval and accumulated extensive safety data. Its short half-life produces physiological pulsatile GH release that maintains natural regulatory mechanisms. For research requiring documented safety profiles or maximum physiological fidelity, sermorelin remains a reference standard.
CJC-1295 comes in two forms with different profiles: - With DAC: Provides convenience through weekly dosing and sustained GH/IGF-1 elevation, but at the cost of pulsatility and with less safety data - Without DAC (Mod GRF 1-29): Offers improved stability over sermorelin while preserving pulsatile action, making it the preferred GHRH component for GHRP combinations
Key Decision Points:
| Priority | Choose | |----------|--------| | Clinical validation | Sermorelin | | Stability + pulsatile | Mod GRF 1-29 | | Dosing convenience | CJC-1295 with DAC | | GHRP combination | Mod GRF 1-29 | | Anti-ageing research | Sermorelin or Mod GRF 1-29 |
The Synergy Principle: Rather than choosing between GHRH analogues alone, the research community increasingly favours combining the chosen GHRH component with a GHRP (such as Ipamorelin or GHRP-2). This dual-receptor approach produces synergistic GH pulses far exceeding either peptide class alone.
*Always consult accredited suppliers and qualified healthcare professionals in your jurisdiction.*
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Sermorelin nor CJC-1295 is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.